NCT00247663已完成2 期
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Safety during treatment
研究概览
简要总结
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients which participated in double blind study
排除标准
- •Patients with intolerable toxicity.
- •Patients which confirmed progressive disease during double blind study.
- •Patients which have received concurrent anti-cancer therapy during double blind study.
研究组 & 干预措施
Letrozole
Experimental
干预措施: Letrozole (Drug)
结局指标
主要结局
Safety during treatment
次要结局
- No secondary outcomes/objectives planned
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular DegenerationNCT06141460Shanghai Refreshgene Technology Co., Ltd.48
已完成
1 期
MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)Diabetes Mellitus, Non-Insulin-DependentNCT00791661Merck Sharp & Dohme LLC24
招募中
1 期
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell LymphomaB-cell MalignancyNCT05106946Fundamenta Therapeutics, Ltd.20
招募中
1 期
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell LymphomaB-cell MalignancyNCT05106907Fundamenta Therapeutics, Ltd.20
已完成
1 期
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy SubjectsAlzheimer DiseaseNCT04920786TrueBinding, Inc.48